Covid-19 roundup: NRx's med gets axed from NIH tri­al over fu­til­i­ty; A new drug for the pan­dem­ic en­ters the clin­ic

There were more deaths in the treat­ment group than place­bo co­hort in an NIH study of NRx Phar­ma­ceu­ti­cals’ al­ready-re­ject­ed Covid-19 drug, and the da­ta safe­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.